Roche's COVID-19 vaccine

GPTKB entity

Statements (65)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:average_temperature -20° C to -80° C
gptkbp:clinical_trial tens of thousands
multiple countries
Phase 3
gptkbp:collaborated_with gptkb:Moderna
gptkbp:community_health gptkb:significant
gptkbp:developed_by gptkb:Roche
gptkbp:dosage_form yes
two doses
gptkbp:effective_date 2021-12-01
gptkbp:funding government and private sectors
https://www.w3.org/2000/01/rdf-schema#label Roche's COVID-19 vaccine
gptkbp:is_effective_against approximately 95%
gptkbp:is_vulnerable_to gptkb:virus
gptkb:logistics
worldwide
high
ongoing
government grants
international organizations
public awareness campaigns
priority
safety and efficacy
rapid
phased approach
essential
equitable
lipid nanoparticle
community immunity
against severe disease
against hospitalization
against symptomatic infection
m RNA technology
limited in early stages
gptkbp:market ongoing
gptkbp:marketed_as gptkb:brand
gptkbp:production_location gptkb:Switzerland
gptkbp:regulatory_compliance gptkb:FDA
gptkb:WHO
gptkb:EMA
gptkbp:route_of_administration intramuscular injection
gptkbp:safety_features well-studied
gptkbp:side_effect fatigue
headache
muscle pain
fever
injection site pain
gptkbp:supply_chain global
gptkbp:target_audience adults
children over 12
gptkbp:targets gptkb:COVID-19
gptkbp:type gptkb:vaccine
gptkbp:vaccine_approval_process expedited
gptkbp:vaccine_collaboration pharmaceutical companies
gptkbp:vaccine_distribution_network established
gptkbp:vaccine_health_equity focus area
gptkbp:vaccine_impact_assessment ongoing research
gptkbp:vaccine_public_health_policy influential
gptkbp:vaccine_public_health_strategy containment of COVID-19
gptkbp:vaccine_public_trust critical for uptake
gptkbp:vaccine_regulatory_compliance stringent
gptkbp:vaccine_research_focus variants of concern
gptkbp:bfsParent gptkb:Lonza_Group
gptkbp:bfsLayer 6